Industry
Biotechnology
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Loading...
Open
1.44
Mkt cap
65M
Volume
630K
High
1.47
P/E Ratio
-0.79
52-wk high
4.02
Low
1.35
Div yield
N/A
52-wk low
1.14
Portfolio Pulse from
December 10, 2024 | 1:15 pm
Portfolio Pulse from
November 09, 2024 | 2:00 pm
Portfolio Pulse from Kaustubh Bagalkote
October 09, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Insights
October 02, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 1:54 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 12:22 pm
Portfolio Pulse from Kaustubh Bagalkote
August 15, 2024 | 5:19 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 6:38 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.